eprosartan eprosartan eprosartan is an angiotensin ii receptor antagonist used for the treatment of high blood pressure. it is marketed in the united states as teveten by abbvie, the spin-off of the pharmaceutical discovery division of abbott laboratories; it is marketed as eprozar by intas pharmaceuticals in india, and by abbott laboratories elsewhere. the compound came into the abbott laboratories cardiovascular pipeline with its acquisition of kos pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the biovail corporation. eprosartanclinical datatrade namestevetenahfs/drugs.commonographmedlineplusa601237license data us dailymed: eprosartan pregnancycategory au: d routes ofadministrationby mouthatc codec09ca02 (who) legal statuslegal status au: s4 (prescription only) us: ℞-only pharmacokinetic databioavailability15% (eprosartan mesylate)metabolismnot metabolizedelimination half-life5 to 9 hoursexcretionkidney 10%, bile duct 90%identifiers iupac name 4-(methyl)benzoic acid cas number133040-01-4 ypubchem cid5281037iuphar/bps588drugbankdb00876 ychemspider4444504 yunii2kh13z0s0ykeggd04040 yas mesylate: d02082 ychebichebi:4814 ychemblchembl813 ycomptox dashboard (epa)dtxsid0022989 chemical and physical dataformulac23h24n2o4smolar mass424.52 g·mol−13d model (jsmol)interactive image smiles o=c(o)\c(=c\c1cnc(n1cc2ccc(c(=o)o)cc2)cccc)cc3sccc3 inchi inchi=1s/c23h24n2o4s/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14h,2-3,6,13,15h2,1h3,(h,26,27)(h,28,29)/b18-12+ ykey:oroafuqrixkemv-ldadjpatsa-n y (verify) eprosartan is sometimes paired with hydrochlorothiazide, whereupon it is marketed in the us as teveten hct and elsewhere as teveten plus. the drug acts on the renin–angiotensin system to decrease total peripheral resistance in two ways. first, it blocks the binding of angiotensin ii to at1 receptors in vascular smooth muscle, causing vascular dilatation. second, it inhibits sympathetic norepinephrine production, further reducing blood pressure. as with other angiotensin ii receptor antagonists, eprosartan is generally better tolerated than enalapril (an ace inhibitor), especially among the elderly. structure activity relationship one feature that compares in eprosartan versus other molecules is that eprosartan is dosed relatively high at 400 to 800 mg/day. eprosartan has an alpha-beta unsaturated hydrocarbon group which makes the compound difficult to absorb and contributes to its instability, thus there is a need for higher doses. the lipophilic aspects of the molecule also contribute to its low bioavailibility.